cohort study recruiting men and women from Hawaii and California, beginning in 1993, and examines lifestyle risk factors and genetic susceptibility to cancer. Only the African American, Japanese American and Native Hawaiian participants of MEC were included in this study. The BioMe BioBank is managed by the Charles Bronfman Institute for Personalized Medicine at Mount Sinai Medical Center. Recruitment began in 2007 and continues at 30 clinical care sites throughout New York City. BioMe participants were African American (25%), Hispanic/Latino, primarily of Caribbean origin (36%), Caucasian (30%) and Others who did not identify with any of the available options (9%). Biobank participants who self-identified as Caucasian were excluded from this analysis. The Global Reference Panel (GRP) was created from Stanford-contributed samples to serve as a population reference dataset for global populations. GRP individuals do not have phenotype data and were only used to aid in the evaluation of genetic ancestry in the PAGE samples. Study protocols were approved for all studies by the appropriate boards at their respective institutions: Fred Hutchinson Cancer Research Center Institutional Review Board (WHI), University of North Carolina Office of Human Research Ethics/IRB (OHRE/IRB; HCHS/SOL), University of Southern California IRB (MEC), University of Hawaii IRB (MEC),
